Literature DB >> 3432450

Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.

J W Tiller1, K P Maguire, B M Davies.   

Abstract

Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A. To study moclobemide effects on the tyramine pressor response, we gave 12 depressed patients (2 males, 10 females; mean age 47, SD 11 years) an i.v. tyramine test after 7 days drug free. The mean (+/- SD) tyramine dose to raise systolic blood pressure 30 mmHg was 5.6 +/- 2.5 mg. Repeat tyramine testing after 2 weeks of treatment with moclobemide (280 +/- 90 mg/d) showed the tyramine dose required was reduced to 2.5 +/- 1.6 mg (n = 8). The mean (+/- SD) increase in sensitivity to tyramine was 2.9 +/- 1.8. Four patients did not have repeated tyramine tests as testing was discontinued because of tyramine-induced cardiac arrhythmias. Moclobemide seems an effective antidepressant with less tyramine sensitivity than MAOIs in current use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3432450     DOI: 10.1016/0165-1781(87)90036-9

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

Review 1.  Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.

Authors:  R J Goldberg
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 3.  Current place of monoamine oxidase inhibitors in the treatment of depression.

Authors:  Kenneth I Shulman; Nathan Herrmann; Scott E Walker
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 4.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.